TIAA CREF Investment Management’s Asterias Biotherapeutics Warrants AST.WS Stock Holding History
Bought
Maintained
Sold
TIAA CREF Investment Management's AST.WS Position: Q3 2017 in Review
TIAA CREF Investment Management sold out of Asterias Biotherapeutics Warrants (AST.WS) in Q3 2017, closing a stake of 153 shares.
TIAA CREF Investment Management first reported a position in AST.WS in Q2 2016 and held it in 5 quarters. The position peaked at $0 in Q2 2017. 3 funds tracked by Wall St. Rank hold AST.WS as of Q3 2017.
- TIAA CREF Investment Management reported no remaining Asterias Biotherapeutics Warrants position as of Q3 2017 after selling out during the quarter.
- TIAA CREF Investment Management sold 153 Asterias Biotherapeutics Warrants shares in Q3 2017.
- TIAA CREF Investment Management first reported a position in Asterias Biotherapeutics Warrants in Q2 2016 and held it in 5 quarters.
- TIAA CREF Investment Management's Asterias Biotherapeutics Warrants position peaked at $0 in Q2 2017.
- 3 funds tracked by Wall St. Rank held Asterias Biotherapeutics Warrants as of Q3 2017.
Based on TIAA CREF Investment Management's 13F filing for Q3 2017, filed 13 Nov 2017.